Format

Send to

Choose Destination
Lancet Respir Med. 2013 Sep;1(7):551-63. doi: 10.1016/S2213-2600(13)70159-0. Epub 2013 Aug 23.

Lung cancer: potential targets for immunotherapy.

Author information

1
Hôpital Européen Georges Pompidou, Service d'Immunologie Biologique, Paris, France; INSERM, U970 PARCC, Université Paris Descartes, Paris, France.
2
INSERM U1015, Institut Gustave Roussy, Villejuif, France; Université Paris Sud, Kremlin Bicêtre, France. Electronic address: zitvogel@igr.fr.

Abstract

Lung cancer is the most common cause of cancer-related mortality worldwide and a therapeutic challenge. Recent success with antibodies blocking immune checkpoints in non-small-cell lung cancers (NSCLC) highlights the potential of immunotherapy for lung cancer treatment, and the need for trials of combination regimens of immunotherapy plus chemotherapy that lead to immunogenic cell death. Here, we review the development of immunogenic cytotoxic compounds, vaccines, and antibodies in NSCLC, in view of their integration into personalised oncology.

PMID:
24461616
DOI:
10.1016/S2213-2600(13)70159-0
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center